Atlanta, GA Clinical Trials Report — May 2026

For individuals in Atlanta, GA, looking to contribute to medical research, May 2026 brings a mix of urgent opportunities and exciting new avenues. With Atlanta hosting a robust research environment, there are currently 1,389 clinical trials actively recruiting across 549 research facilities, offering diverse ways to participate.

A significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals. A total of 96 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Act Now: Trials Closing Soon

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Heart failure (4 trials)
• Advanced breast cancer (3 trials)
• Sickle cell disease (3 trials)
• Primary peritoneal cancer (2 trials)
• Acute lymphoblastic leukemia (2 trials)
• Mild cognitive impairment (2 trials)
• Fallopian tube cancer (2 trials)
• Breast cancer (2 trials)
• Autism spectrum disorder (2 trials)
• Gastric cancer (2 trials)

New Research Opportunities Emerge in May

This month, Atlanta saw the opening of 23 new clinical trials, an increase from the 18 trials that launched in April 2026. This growth signifies a vibrant and expanding research landscape in the city.

May brings several high-profile new trials to Atlanta, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• Also from Novo Nordisk A/S, two Phase 3 studies focus on obesity and obstructive sleep apnoea: NCT07571005, "AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea," and NCT07571109, "AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea." Each of these studies targets 300 participants.
• RAI Services Company is sponsoring NCT07598136, "A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers," involving 1,280 participants to assess the impact of electronic nicotine delivery systems on smoking abstinence.
• The University of California, Davis is leading NCT07580183, "Spatial Scene Recognition Memory in Epilepsy Surgery," an investigation into the anatomical and physiological basis of spatial scene recognition memory in patients with temporal lobe epilepsy, with 620 participants.
• Emory University is sponsoring NCT07563517, "Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches & Across INcarceration Settings," a study with 550 participants to learn whether a virtual peer recovery coach intervention can improve engagement in addiction treatment among incarcerated adults.

New trials this month are exploring a range of conditions, with the most frequent being obesity (3 trials), congenital heart disease (2 trials), obstructive sleep apnoea (2 trials), and overweight (2 trials). Drug trials account for the largest share of new studies, with 8 new drug trials, followed by 7 other types of studies and 5 device trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 23 new trials launched this month, 7 are actively seeking healthy volunteers. Across Atlanta, a total of 118 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Atlanta's Leading Research Facilities

Atlanta is home to some of the region's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Emory University (194 trials)
• Emory University Hospital/Winship Cancer Institute (130 trials)
• Emory University Hospital Midtown (120 trials)
• Emory University Hospital (87 trials)
• Emory Saint Joseph's Hospital (84 trials)
• Children's Healthcare of Atlanta (51 trials)
• Grady Health System (49 trials)
• Northside Hospital (46 trials)
• Research Site (44 trials)
• Emory University School of Medicine (44 trials)
• Children's Healthcare of Atlanta - Arthur M Blank Hospital (36 trials)
• Winship Cancer Institute of Emory University (31 trials)

These institutions, particularly those within the Emory University system, offer a broad spectrum of research, from comprehensive medical studies to specialized care at Children's Healthcare of Atlanta and cancer research at the Winship Cancer Institute.

Who Can Participate? Eligibility and Sponsors

Participation in clinical trials is open to a diverse range of individuals. Of the 23 new trials launched this month, 15 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 5 new trials include children, and 2 are male-only. No new trials this month are female-only.

Academic institutions continue to play a vital role in Atlanta's research ecosystem, with Emory University sponsoring 4 new trials. Industry sponsors like Novo Nordisk A/S (3 trials) and Carelon Research (2 trials) are also driving significant research efforts, reflecting a strong collaboration between academic and commercial research.

Broadening Your Search: Nearby Options in Georgia

While Atlanta offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Georgia. Cities with active trials include:

• Decatur (3 trials)
• Gainesville (3 trials)
• Snellville (2 trials)
• Lawrenceville (2 trials)
• Woodstock (2 trials)
• Conyers (2 trials)
• Savannah (2 trials)
• Tucker (1 trial)

As we move through May, Atlanta's dynamic research community continues to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and make a tangible impact on scientific progress.